Kendra A Porath
Mayo Clinic
DNA damageIonizing radiationSensitizationAntibody-drug conjugateMelanomaBlood–brain barrierBrain tumorEpidermal growth factor receptorDrug deliveryDrugDepatuxizumab mafodotinCancer researchRadiation therapyDNASignal transductionDNA-PKcsMedicineDistribution (pharmacology)
Publications 2
#1Bianca Maria Marin (Mayo Clinic)H-Index: 1
#2Kendra A Porath (Mayo Clinic)
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 30 authors...
BACKGROUND Antibody drug conjugates (ADCs) targeting the epidermal growth factor receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic strategy for glioblastoma (GBM) but recent clinical trials did not demonstrate a survival benefit. Understanding the mechanisms of failure for this promising strategy is critically important. METHODS PDX models were employed to study efficacy of systemic vs intracranial delivery of Depatux-M. Immunofluorescence and MALDI-MSI wer...
#1Jianxiong Ji (Mayo Clinic)
#2Emily L. Smith (Mayo Clinic)H-Index: 1
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 22 authors...